Services

In March 2009, the Chinese government laid out its ambitious RMB 850 billion (USD 125 billion) healthcare reform plan. This reform will reshape the landscape for China´s pharmaceutical and healthcare industries  over the next decade.

Whether you are already operating in China or are looking to enter the Chinese market, it is important to understand the road ahead.

At CHEURAM, we have the knowledge and experience to help you navigate the complex maze of rules and regulations, identify opportunities and challenges, and manage risks.

We have been advising pharmaceuticals, medical devices, healthcare products, manufacturers and distributors, medical and research institutions, clinical research organizations, as well as health and regulatory authorities on M&A. We have experience in alliance and joint venture transactions and a broad spectrum of regulatory and compliance issues.

For global players operating in the region or Asian companies or suppliers involved in the industry, our lawyers provide the legal and business solutions required for strategic and operational success in the Greater China region.